EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Lecanemab: Appropriate Use Recommendations by Korean Dementia Association

Kee Hyung Park iD, Geon Ha Kim iD, Chi-Hun Kim iD, Seong-Ho Koh iD, So Young Moon iD, Young Ho Park iD, Sang Won Seo iD, Bora Yoon iD, Jae-Sung Lim iD, Byeong C Kim iD, Hee-Jin Kim iD, Hae Ri Na iD und 9 weitere

Dementia and Neurocognitive Disorders · 2024 · 23 (4) · 165

DOI: 10.12779/dnd.2024.23.4.165 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Dementia and Neurocognitive Disorders, 2024. Verfasst von Kee Hyung Park und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lecanemab (product name Leqembi®) is an anti-amyloid monoclonal antibody treatment approved for use in Korea for patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease. The Korean Dementia Association has created recommendations for the appropriate use of lecanemab to assist clinicians. These recommendations include selecting patients for administration, necessary pre-administration tests and preparations, administration methods, monitoring for amyloid related imaging abnormalities (ARIA), and communication with patients and caregivers. Lecanemab is recommended for patients with MCI or mild dementia who confirmed positive amyloid biomarkers, and should not be administered to patients with severe hypersensitivity to lecanemab or those unable to undergo magnetic resonance imaging (MRI) evaluation. To predict the risk of ARIA before administration, apolipoprotein E genotyping is conducted, and regular brain MRI evaluations are recommended to monitor for ARIA during treatment. The most common adverse reactions are infusion-related reactions, which require appropriate management upon occurrence. Additional caution is needed when co-administering with anticoagulants or tissue plasminogen activator due to the risk of macrohemorrhage. Clinicians should consider the efficacy and necessary conditions for administration, as well as the safety of lecanemab, to make a comprehensive decision regarding its use.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer's DiseaseAmyloidLecanemabMagnetic Resonance ImagingMonoclonal Antibody

Autor:innen und Institutionen

  • Department of Neurology, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.
  • Department of Neurology, Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine, Seoul, Korea.
  • Department of Neurology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea.
  • Department of Neurology, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea.
  • Department of Neurology, Ajou University Hospital, Ajou University School of Medicine, Suwon, Korea.
  • Department of Neurology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.

ORCID-Profile: Kee Hyung Park, Geon Ha Kim, Chi-Hun Kim, Seong-Ho Koh, So Young Moon, Young Ho Park, Sang Won Seo, Bora Yoon, Jae-Sung Lim, Byeong C Kim, Hee-Jin Kim, Hae Ri Na, YongSoo Shim, YoungSoon Yang, Chan-Nyoung Lee, Hak Young Rhee, San Jung, Jee Hyang Jeong, Hojin Choi, Dong Won Yang, Seong Hye Choi

Zitieren

APA

Park, K. H., Kim, G. H., Kim, C. H., Koh, S. H., Moon, S. Y., Park, Y. H., Seo, S. W., Yoon, B., Lim, J. S., Kim, B. C., Kim, H. J., Na, H. R., Shim, Y., Yang, Y., Lee, C. N., Rhee, H. Y., Jung, S., Jeong, J. H., Choi, H., …, & Choi, S. H. (2024). Lecanemab: Appropriate Use Recommendations by Korean Dementia Association. Dementia and Neurocognitive Disorders, 23(4), 165. https://doi.org/10.12779/dnd.2024.23.4.165

Vancouver

Park KH, Kim GH, Kim CH, Koh SH, Moon SY, Park YH, et al. Lecanemab: Appropriate Use Recommendations by Korean Dementia Association. Dementia and Neurocognitive Disorders. 2024;23(4):165. doi:10.12779/dnd.2024.23.4.165

BibTeX
@article{Park2024,
  author = {Park, Kee Hyung and Kim, Geon Ha and Kim, Chi-Hun and Koh, Seong-Ho and Moon, So Young and Park, Young Ho and Seo, Sang Won and Yoon, Bora and Lim, Jae-Sung and Kim, Byeong C and Kim, Hee-Jin and Na, Hae Ri and Shim, YongSoo and Yang, YoungSoon and Lee, Chan-Nyoung and Rhee, Hak Young and Jung, San and Jeong, Jee Hyang and Choi, Hojin and Yang, Dong Won and Choi, Seong Hye},
  title = {Lecanemab: Appropriate Use Recommendations by Korean Dementia Association},
  journal = {Dementia and Neurocognitive Disorders},
  year = {2024},
  volume = {23},
  number = {4},
  pages = {165},
  doi = {10.12779/dnd.2024.23.4.165}
}
Kostenlos starten →